U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Stage II Adult Diffuse Small Cleaved Cell Lymphoma

MedGen UID:
83604
•Concept ID:
C0280147
•
Neoplastic Process

Definition

Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single associated extralymphatic organ or site and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE). Note: The number of lymph node regions involved may be indicated by a subscript (e.g., II3). (from PDQ) [from NCI]

Professional guidelines

PubMed

Extranodal Head and Neck Mantle Cell Lymphoma: Characteristics, Treatment, and Survival.
Breen CT, Chao J, Mehra S, Kohli N
Ann Otol Rhinol Laryngol 2022 Apr;131(4):412-419. Epub 2021 Jun 17 doi: 10.1177/00034894211025171. PMID: 34137303
Treatment strategies in mantle cell lymphoma.
Maddocks K, Blum KA
Cancer Treat Res 2015;165:251-70. doi: 10.1007/978-3-319-13150-4_10. PMID: 25655613
Diagnosis and management of natural killer-cell malignancies.
Ishida F, Kwong YL
Expert Rev Hematol 2010 Oct;3(5):593-602. doi: 10.1586/ehm.10.51. PMID: 21083476

Recent clinical studies

Etiology

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS
Lancet Oncol 2022 Jan;23(1):91-103. Epub 2021 Dec 8 doi: 10.1016/S1470-2045(21)00591-X. PMID: 34895487
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH
Br J Haematol 2016 Nov;175(3):410-418. Epub 2016 Jul 5 doi: 10.1111/bjh.14241. PMID: 27378674
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS
Blood 2015 Feb 26;125(9):1403-10. Epub 2015 Jan 7 doi: 10.1182/blood-2014-10-604561. PMID: 25568347Free PMC Article
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group
Lancet Oncol 2006 May;7(5):379-91. doi: 10.1016/S1470-2045(06)70664-7. PMID: 16648042
A predictive model for aggressive non-Hodgkin's lymphoma.
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402. PMID: 8141877

Diagnosis

Primary cardiac lymphoma.
Yin K, Brydges H, Lawrence KW, Wei Y, Karlson KJ, McAneny DB, Edwards NM, Reardon MJ, Dobrilovic N
J Thorac Cardiovasc Surg 2022 Aug;164(2):573-580.e1. Epub 2020 Oct 7 doi: 10.1016/j.jtcvs.2020.09.102. PMID: 33158567
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH
Br J Haematol 2016 Nov;175(3):410-418. Epub 2016 Jul 5 doi: 10.1111/bjh.14241. PMID: 27378674
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS
Blood 2015 Feb 26;125(9):1403-10. Epub 2015 Jan 7 doi: 10.1182/blood-2014-10-604561. PMID: 25568347Free PMC Article
Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K
J Clin Oncol 2009 Nov 20;27(33):5594-600. Epub 2009 Oct 5 doi: 10.1200/JCO.2009.23.8295. PMID: 19805668
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group
Lancet Oncol 2006 May;7(5):379-91. doi: 10.1016/S1470-2045(06)70664-7. PMID: 16648042

Therapy

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS
Lancet Oncol 2022 Jan;23(1):91-103. Epub 2021 Dec 8 doi: 10.1016/S1470-2045(21)00591-X. PMID: 34895487
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators
Lancet Oncol 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9 doi: 10.1016/S1470-2045(18)30379-6. PMID: 30100375
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH
Br J Haematol 2016 Nov;175(3):410-418. Epub 2016 Jul 5 doi: 10.1111/bjh.14241. PMID: 27378674
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS
Blood 2015 Feb 26;125(9):1403-10. Epub 2015 Jan 7 doi: 10.1182/blood-2014-10-604561. PMID: 25568347Free PMC Article
A predictive model for aggressive non-Hodgkin's lymphoma.
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402. PMID: 8141877

Prognosis

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH
Br J Haematol 2016 Nov;175(3):410-418. Epub 2016 Jul 5 doi: 10.1111/bjh.14241. PMID: 27378674
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD
Lancet Oncol 2016 Aug;17(8):1081-1093. Epub 2016 Jun 23 doi: 10.1016/S1470-2045(16)30097-3. PMID: 27345636
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS
Blood 2015 Feb 26;125(9):1403-10. Epub 2015 Jan 7 doi: 10.1182/blood-2014-10-604561. PMID: 25568347Free PMC Article
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group
Lancet Oncol 2006 May;7(5):379-91. doi: 10.1016/S1470-2045(06)70664-7. PMID: 16648042
A predictive model for aggressive non-Hodgkin's lymphoma.
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402. PMID: 8141877

Clinical prediction guides

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS
Lancet Oncol 2022 Jan;23(1):91-103. Epub 2021 Dec 8 doi: 10.1016/S1470-2045(21)00591-X. PMID: 34895487
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators
Lancet Oncol 2018 Sep;19(9):1192-1204. Epub 2018 Aug 9 doi: 10.1016/S1470-2045(18)30379-6. PMID: 30100375
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH
Br J Haematol 2016 Nov;175(3):410-418. Epub 2016 Jul 5 doi: 10.1111/bjh.14241. PMID: 27378674
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS
Blood 2015 Feb 26;125(9):1403-10. Epub 2015 Jan 7 doi: 10.1182/blood-2014-10-604561. PMID: 25568347Free PMC Article
A predictive model for aggressive non-Hodgkin's lymphoma.
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med 1993 Sep 30;329(14):987-94. doi: 10.1056/NEJM199309303291402. PMID: 8141877

Recent systematic reviews

Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma.
Adams HJ, Nievelstein RA, Kwee TC
J Comput Assist Tomogr 2017 Jan;41(1):98-103. doi: 10.1097/RCT.0000000000000485. PMID: 27560022
Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique.
Arden-Close E, Pacey A, Eiser C
Leuk Lymphoma 2010 Apr;51(4):628-40. doi: 10.3109/10428191003587263. PMID: 20218810
Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C, Hind D, Brewer N, Abbott V
Health Technol Assess 2004 Sep;8(37):iii, ix-xi, 1-82. doi: 10.3310/hta8370. PMID: 15361313
A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma.
Gustavsson A, Osterman B, Cavallin-Ståhl E
Acta Oncol 2003;42(5-6):605-19. doi: 10.1080/02841860310014435. PMID: 14596518
A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma.
Kimby E, Brandt L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care
Acta Oncol 2001;40(2-3):198-212. doi: 10.1080/02841860151116268. PMID: 11441932

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...